XRAY moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend. In 23 of 34 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 68%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on XRAY as a result. In 56 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for XRAY just turned positive on October 09, 2026. Looking at past instances where XRAY's MACD turned positive, the stock continued to rise in 30 of 53 cases over the following month. The odds of a continued upward trend are 57%.
The 10-day moving average for XRAY crossed bullishly above the 50-day moving average on November 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 4 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 36%.
Following a +2.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where XRAY advanced for three days, in 174 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
The 10-day RSI Indicator for XRAY moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 21 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 63 cases where XRAY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XRAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
XRAY broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XRAY entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.396) is normal, around the industry mean (4.964). P/E Ratio (-3.465) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.601) is also within normal values, averaging (4.143). XRAY's Dividend Yield (0.068) is considerably higher than the industry average of (0.005). P/S Ratio (0.557) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating fairly steady price growth. XRAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XRAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
XWEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 44 of 49 cases where XWEL's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where XWEL's RSI Indicator exited the oversold zone, 41 of 47 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XWEL as a result. In 80 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for XWEL turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 42 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XWEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for XWEL entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-2.728) is normal, around the industry mean (67.298). P/E Ratio (-0.113) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.220) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. XWEL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XWEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
XRAY | XWEL | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 23 | 61 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 100 | |
PRICE GROWTH RATING 1..100 | 57 | 89 | |
P/E GROWTH RATING 1..100 | 15 | 11 | |
SEASONALITY SCORE 1..100 | 75 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XRAY's Valuation (6) in the Medical Specialties industry is somewhat better than the same rating for XWEL (49) in the Other Consumer Services industry. This means that XRAY’s stock grew somewhat faster than XWEL’s over the last 12 months.
XRAY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as XWEL (100) in the Other Consumer Services industry. This means that XRAY’s stock grew similarly to XWEL’s over the last 12 months.
XRAY's SMR Rating (97) in the Medical Specialties industry is in the same range as XWEL (100) in the Other Consumer Services industry. This means that XRAY’s stock grew similarly to XWEL’s over the last 12 months.
XRAY's Price Growth Rating (57) in the Medical Specialties industry is in the same range as XWEL (89) in the Other Consumer Services industry. This means that XRAY’s stock grew similarly to XWEL’s over the last 12 months.
XWEL's P/E Growth Rating (11) in the Other Consumer Services industry is in the same range as XRAY (15) in the Medical Specialties industry. This means that XWEL’s stock grew similarly to XRAY’s over the last 12 months.
| XRAY | XWEL | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 88% | 1 day ago 87% |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 85% |
| Momentum ODDS (%) | 1 day ago 62% | 1 day ago 90% |
| MACD ODDS (%) | 2 days ago 57% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 74% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 63% | 1 day ago 90% |
| Advances ODDS (%) | 1 day ago 60% | N/A |
| Declines ODDS (%) | 6 days ago 73% | 2 days ago 89% |
| BollingerBands ODDS (%) | 1 day ago 82% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 75% | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
XRAY’s FA Score shows that 2 FA rating(s) are green while XWEL’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
XRAY’s TA Score shows that 5 TA indicator(s) are bullish while XWEL’s TA Score has 3 bullish TA indicator(s).
XRAY (@Pharmaceuticals: Other) experienced а -0.31% price change this week, while XWEL (@Medical Specialties) price change was -21.36% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +1.96%. For the same industry, the average monthly price growth was +6.35%, and the average quarterly price growth was +22.73%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -4.92%. For the same industry, the average monthly price growth was -5.08%, and the average quarterly price growth was +38.31%.
XRAY is expected to report earnings on Mar 04, 2027.
XWEL is expected to report earnings on Nov 13, 2026.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (-4.92% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
A.I.dvisor indicates that over the last year, XRAY has been loosely correlated with NVST. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if XRAY jumps, then NVST could also see price increases.
| Ticker / NAME | Correlation To XRAY | 1D Price Change % | ||
|---|---|---|---|---|
| XRAY | 100% | +0.62% | ||
| NVST - XRAY | 62% Loosely correlated | -2.01% | ||
| ALGN - XRAY | 60% Loosely correlated | -1.25% | ||
| QDEL - XRAY | 50% Loosely correlated | +3.39% | ||
| KIDS - XRAY | 48% Loosely correlated | +0.57% | ||
| STE - XRAY | 46% Loosely correlated | -0.33% | ||
More | ||||
A.I.dvisor tells us that XWEL and LUCY have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XWEL and LUCY's prices will move in lockstep.
| Ticker / NAME | Correlation To XWEL | 1D Price Change % | ||
|---|---|---|---|---|
| XWEL | 100% | +9.62% | ||
| LUCY - XWEL | 29% Poorly correlated | -1.92% | ||
| DRIO - XWEL | 28% Poorly correlated | -11.09% | ||
| XRAY - XWEL | 23% Poorly correlated | +0.62% | ||
| NVCR - XWEL | 22% Poorly correlated | +1.52% | ||
| MBAI - XWEL | 21% Poorly correlated | +8.46% | ||
More | ||||